Type 2 diabetes drug may reduce colorectal cancer risk

Glucagon-like peptide 1 receptor agonists significantly lowered the risk for colorectal cancer in patients with type 2 diabetes compared with other diabetes medications, according to a research letter in JAMA Oncology.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced the risk for colorectal cancer (CRC) by 44% compared with insulin and by 25% compared with metformin. Researchers observed these risk reductions in overweight, obese and nonobese patients alike.
“We were surprised to find that the GLP-1 RAs have similar or even stronger effect in preventing colorectal cancer

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart